Filing Analysis
Sanara MedTech Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Quarter ended June 30, 2026
- The filing includes Exhibit 99.1 containing the press release of financial results.
Sanara MedTech Inc. (SMTI) has entered into a definitive merger agreement to be acquired by MiMedx Group, Inc. The deal structure involves a combination of $33.00 in cash and 0.4735 shares of Parent common stock per share.
🚩 Red Flags
- Amendment filed specifically to correct significant errors regarding termination fee amounts ($22.5M vs $9.6M and vice versa).
- The company will be delisted from Nasdaq upon consummation of the merger.
- Significant termination fees (approx. $9.7M for SMTI) create a high cost for switching to a superior proposal.
📋 Key Facts
- Merger Agreement dated July 29, 2026, with MiMedx Group, Inc. (Parent) and Mustang Merger Sub, Inc.
- Merger consideration: $33.00 cash + 0.4735 shares of Parent stock per share of SMTI.
- The transaction is expected to result in SMTI becoming a wholly-owned subsidiary of MiMedx Group, Inc.
- Termination fee for Company (SMTI): $9,660,336.00 if entering a superior proposal or failing stockholder approval under specific conditions.
- Termination fee for Parent (MiMedx): $22,540,785.00 if the company terminates due to parent's failure to consummate.
- The merger is subject to stockholder approval and customary closing conditions including antitrust/HSR clearance.
- This filing is an Amendment (8-K/A) to correct error in termination fee amounts reported in the original 8-K.
Sanara MedTech Inc. (SMTI) has entered into a definitive merger agreement to be acquired by MiMedx Group, Inc. The transaction will result in SMTI becoming a wholly-owned subsidiary of Parent and being delisted from the Nasdaq.
🚩 Red Flags
- Significant termination fee ($22.5M) creates a high barrier for the company to pursue alternative superior proposals.
- The transaction involves an issuance of Parent stock, introducing market volatility risk into the final merger consideration value.
📋 Key Facts
- Merger consideration: $33.00 per share in cash plus 0.4735 shares of MiMedx Group, Inc. common stock (valued at ~$2.00/share).
- Total merger consideration includes both cash and equity components.
- The deal is subject to stockholder approval and customary closing conditions including HSR antitrust clearance.
- Termination fee: $22,540,785 payable by SMTI if it terminates for a superior proposal; $9,660,336 payable by Parent if they fail to consummate the merger.
- The deal is expected to close on or before July 29, 2027 (with potential extension to Jan 2028).
- SMTI will be delisted from Nasdaq upon completion.
Sanara MedTech Inc. reported the results of its Annual Meeting of Shareholders held on June 4, 2026. Shareholders approved the election of the Board of Directors, the ratification of the independent auditor, and executive compensation matters.
📋 Key Facts
- Annual Meeting held on June 4, 2026, with 6,701,593 shares represented.
- Nine directors were elected to the Board for one-year terms.
- Weaver and Tidwell, L.L.P. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Shareholders approved executive compensation on an advisory basis.
- The company will now conduct advisory votes on executive compensation every three years, with the next vote expected in 2029.
Sanara MedTech Inc. has mutually terminated its Transaction Advisory Services Agreement with The Catalyst Group, Inc., effective June 2, 2026. The termination is attributed to a shift in corporate strategy toward soft tissue repair and bone fusion products.
🚩 Red Flags
- The agreement was a related-party transaction: The Company's Chairman, Ronald T. Nixon, is the founder and managing partner of The Catalyst Group, Inc.
- The Catalyst Group and its affiliates are significant shareholders, owning more than 5% of the Company's outstanding common stock.
📋 Key Facts
- The Services Agreement was originally effective as of March 1, 2023.
- The agreement was terminated via a Mutual Termination Agreement on June 2, 2026.
- No fee or penalty was paid by the Company to effectuate the termination.
- Indemnification and confidentiality covenants remain in effect.
- The Company is shifting its strategic focus to soft tissue repair and bone fusion products for the surgical market.
Sanara MedTech Inc. reported its financial results for the first quarter ended March 31, 2026. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 11, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information in the report and the attached press release is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Sanara MedTech Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the 8-K filing on March 24, 2026.
📋 Key Facts
- Reporting date of March 24, 2026, for the fiscal period ended December 31, 2025.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the press release detailing the financial performance.
Sanara MedTech Inc. furnished an investor presentation in connection with its participation in the TD Cowen 46th Annual Health Care Conference. The presentation outlines the company's strategic priorities and provides anticipated revenue guidance for the 2026 fiscal year.
📋 Key Facts
- The company is presenting at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026.
- The filing includes an investor presentation as Exhibit 99.1.
- The presentation contains anticipated revenue figures for the 2026 fiscal year.
- The information is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Sanara MedTech Inc. issued an 8-K to announce the release of preliminary financial results for the fourth quarter and full year of fiscal year 2025.
📋 Key Facts
- Report date: January 23, 2026
- The filing pertains to Item 2.02 (Results of Operations and Financial Condition)
- Preliminary financial results for Q4 and FY 2025 were announced via press release on January 23, 2026
- Signed by Elizabeth B. Taylor, Chief Financial Officer
Sanara MedTech Inc. is furnishing an investor presentation in connection with its upcoming participation at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The presentation outlines the company's strategic priorities and goals for fiscal year 2026.
📋 Key Facts
- Company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025.
- The presentation includes a summary of the Company’s priorities and strategy for the 2026 fiscal year.
- Information is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Sanara MedTech Inc. filed an 8-K to furnish its quarterly financial results for the period ending September 30, 2025. The filing serves as a formal announcement of the earnings press release.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The company furnished Exhibit 99.1 containing the press release regarding financial results.
Sanara MedTech Inc. has announced a strategic realignment involving the discontinuation of its Tissue Health Plus operations, effective November 11, 2025.
🚩 Red Flags
- Discontinuation of a primary product/business line (Tissue Health Plus) often indicates significant impairment charges or loss of revenue stream.
- Strategic realignments in micro-cap medtech companies are frequently precursors to liquidity issues or restructuring costs.
📋 Key Facts
- Company initiated a 'strategic realignment' on November 11, 2025.
- The realignment includes the discontinuation of the 'Tissue Health Plus' business line.
- The announcement was made via press release furnished as Exhibit 99.1.
Sanara MedTech Inc. announced a leadership transition involving the appointment of Seth D. Yon as new CEO and President, effective September 15, 2025. The current CEO, Ronald T. Nixon, will step down from his executive role but remain on the Board as Executive Chairman.
🚩 Red Flags
- CEO transition occurring relatively quickly after the previous CEO was appointed in May 2024 (approx. 15 months).
📋 Key Facts
- Seth D. Yon appointed as President and CEO, effective Sept 15, 2025.
- Ronald T. Nixon resigning as CEO; transitioning to Executive Chairman of the Board.
- Yon's compensation includes a $600,000 base salary and a one-time $1.0 million restricted stock grant.
- Board size increased from eight (8) to nine (9) directors with Yon's appointment.
- Ashley Mackey designated as Principal Accounting Officer; Elizabeth B. Taylor remains CFO but steps down as PAO.
Sanara MedTech Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing consists of a press release issued on August 13, 2025.
📋 Key Facts
- Company announced financial results for the quarter ended June 30, 2025.
- Report date: August 13, 2025.
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition).
Sanara MedTech Inc. held its Annual Meeting of Shareholders on May 22, 2025, where shareholders approved the election of eight directors and the ratification of Weaver and Tidwell, L.L.P. as independent auditors. The company also furnished an updated investor presentation via Regulation FD disclosure.
📋 Key Facts
- Annual Meeting held on May 22, 2025, with 6,781,075 shares present in person or by proxy.
- Eight directors were elected to one-year terms: Ronald T. Nixon, Robert A. DeSutter, Roszell Mack III, Eric D. Major, Keith G. Myers, Sara N. Ortwein, Ann Beal Salamone, and Eric D. Tanzberger.
- Shareholders ratified Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for fiscal year 2025.
- The company updated its investor presentation on May 27, 2025.
Sanara MedTech Inc. announced the retirement of Michael D. McNeil, who serves as Chief Accounting Officer and Chief Administrative Officer, effective August 19, 2025. CFO Elizabeth B. Taylor will assume his duties as principal accounting officer upon his departure.
🚩 Red Flags
- Succession planning involves the CFO assuming additional significant responsibilities (Principal Accounting Officer), which can increase workload and oversight risk in micro-cap environments.
📋 Key Facts
- Michael D. McNeil is retiring from CAO and CAO roles on August 19, 2025.
- The company is negotiating a consulting arrangement with Mr. McNeil for transition and advisory services post-retirement.
- Elizabeth B. Taylor (CFO) will take over as principal accounting officer effective August 19, 2025.
Sanara MedTech Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing serves as a formal announcement of the company's recent operating and financial performance via a press release.
📋 Key Facts
- Report date: May 14, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes Exhibit 99.1 containing the quarterly press release
- Signed by Michael D. McNeil, Chief Accounting Officer and Chief Administrative Officer
Sanara MedTech Inc. is furnishing an investor presentation in connection with its upcoming appearance at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025.
📋 Key Facts
- The company is providing a copy of an investor presentation (Exhibit 99.1) to comply with Regulation FD disclosure requirements.
- The presentation is intended for use in meetings with investors and analysts at the Planet MicroCap Showcase: VEGAS 2025.
- The event is scheduled for April 23, 2025, one day after the filing date.
Sanara MedTech Inc. completed the acquisition of CarePICS, LLC on April 1, 2025, for an aggregate cash purchase price of $2.0 million plus the assumption of $1.65 million in existing debt. The acquisition includes significant contingent earnout obligations based on SaaS EBITDA and patient volume.
🚩 Red Flags
- Significant contingent liabilities: Potential for up to $10M in long-term earnouts and additional EBITDA-based payments.
- High cost of debt: The company is utilizing a term loan with a 13.25% interest rate to fund acquisitions and working capital.
- Complex earnout terms: Earnouts include penalties for funding the SaaS P&L in excess of $110k/month, which can be complex to track.
📋 Key Facts
- Acquisition closed on April 1, 2025.
- Total cash consideration for equity: $2.0 million (includes transaction expenses).
- Company paid an additional $1.65 million to satisfy CarePICS' existing indebtedness.
- Earnout structure includes two periods ending March 31, 2027, based on SaaS P&L EBITDA and funding levels.
- Long-term 'Purchaser Value Earnouts' up to $10.0 million based on patient volume ($5.00 per patient/year) for up to 10 years.
- The company recently executed a 'Third Borrowing' of $12.25 million under an existing term loan with CRG Servicing LLC, bearing 13.25% interest.
Sanara MedTech Inc. filed an 8-K to furnish its press release announcing financial results for the quarter and fiscal year ended December 31, 2024.
📋 Key Facts
- The filing is a standard earnings release under Item 2.02.
- Reporting period covered: Quarter and Year ended December 31, 2024.
- Date of report: March 25, 2025.
Sanara MedTech Inc. has appointed Elizabeth B. Taylor as the new Chief Financial Officer, effective January 15, 2025. Concurrently, existing CFO Michael D. McNeil is transitioning to the role of Chief Accounting Officer and Chief Administrative Officer.
🚩 Red Flags
- Sudden transition of a long-tenured CFO (since April 2018) to a CAO/CAO role may indicate internal restructuring or friction, though not explicitly stated.
- Significant severance packages for both the new and transitioning officers.
📋 Key Facts
- Elizabeth B. Taylor appointed as CFO/Principal Financial Officer on Jan 15, 2025; base salary $250,000 plus up to 75% annual cash bonus and 75% of base salary in restricted stock.
- Michael D. McNeil transitioned from CFO to Chief Accounting Officer (CAO) and Chief Administrative Officer (CAO), including the role of principal accounting officer.
- McNeil's compensation was amended: annualized base salary increased to $234,000 and annual cash bonus eligibility increased from 50% to 75%.
- Both new/amended agreements include one-year severance provisions in the event of termination without cause or change of control.
- No family relationships or related-party transactions involving the new officers were disclosed.
Sanara MedTech Inc. entered into a Licensing and Distribution Agreement with Biomimetic Innovation Limited (BMI) for exclusive U.S. rights to OsStic and ARC medical products. As part of the deal, Sanara is making an equity investment in BMI totaling up to €8.0 million for a 12.5% stake.
🚩 Red Flags
- Contingent capital commitment: The remaining €4.0 million of the investment is tied to future milestones, creating potential future cash outflows.
- Minimum royalty obligations: Guaranteed low-to-mid six-figure annual payments starting after regulatory approval regardless of sales volume.
📋 Key Facts
- Acquired exclusive U.S. marketing, sales, and distribution rights for OsStic (bone void filler) and ARC (delivery technology).
- License term is an initial five years with automatic two-year renewals at the Company's discretion.
- Royalties to BMI: Mid-single digit range for OsStic; ARC terms to be negotiated later.
- Minimum royalty payments: Low to mid six-figure range for each of the first three years following regulatory approval.
- Subscription Agreement: Sanara to contribute up to €8.0 million for 16,460 ordinary shares (approx. 12.5% equity in BMI).
- Initial cash investment made on Jan 16, 2025: ~€3.0 million; previously announced convertible loan converted to €1.0 million of equity.
- Remaining €4.0 million contribution is contingent upon achieving specific development and regulatory milestones.
- Sanara's Chief Corporate Development & Strategy Officer, Tyler Palmer, appointed to BMI's board.
Sanara MedTech Inc. issued a press release announcing preliminary financial results for the fourth quarter and full year of 2024.
📋 Key Facts
- Report date: January 21, 2025
- The filing pertains to Item 2.02 (Results of Operations and Financial Condition)
- Preliminary financial results for Q4 and FY 2024 were announced via press release
- Exhibit 99.1 contains the full details of the preliminary results
Sanara MedTech Inc. is furnishing an investor presentation intended for use at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.
📋 Key Facts
- The company is presenting at the Piper Sandler 36th Annual Healthcare Conference in New York, NY.
- Date of report: December 4, 2024.
- The presentation is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Sanara MedTech Inc. filed an 8-K to announce the release of its financial results for the quarter ended September 30, 2024 and to provide an investor presentation.
📋 Key Facts
- Financial results were announced on November 12, 2024, for the period ending September 30, 2024.
- The company scheduled a webcast/investor meeting for November 13, 2024, at 9:00 a.m. ET.
- Exhibits include a press release (99.1) and an investor presentation (99.2).
Sanara MedTech Inc. announced the resignation of director James W. Stuckert and the appointment of Keith Myers to the Board, effective October 4, 2024.
🚩 Red Flags
- None identified; the resignation was explicitly stated to be non-disagreement based.
📋 Key Facts
- James W. Stuckert resigned from the Board and all committees on October 4, 2024; he will remain as Director Emeritus in a non-voting capacity.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Keith Myers has been appointed to fill the vacancy and will serve on the Corporate Development Committee.
- Mr. Myers is a co-founder of LHC Group (merged with Optum, Inc. in 2023) and has extensive healthcare leadership experience.
- Mr. Myers' compensation includes an annual retainer of $90,000 for Board service and $5,000 for Committee service, payable in restricted stock.
Sanara MedTech Inc. has entered into a formal executive employment agreement with Ronald T. Nixon, who will serve as CEO for an initial one-year term effective September 1, 2024.
🚩 Red Flags
- Significant cash and equity-based compensation package for a micro-cap entity.
- Standard but high-cost 'Change of Control' severance provisions (2 years of base salary).
📋 Key Facts
- Ronald T. Nixon appointed CEO effective September 1, 2024.
- Annual base salary set at $350,000.
- One-time cash bonus of $125,000 to be paid following the execution date.
- Eligible for annual performance-based restricted stock awards up to $625,000.
- Severance package includes one year of base salary for termination without 'Cause' or by CEO for 'Good Reason'.
- Double severance (two years of base salary) in the event of a Change of Control within one year of employment.
Sanara MedTech Inc. (SMTI) acquired a 6.64% equity stake in ChemoMouthpiece, LLC for $5.0 million and secured exclusive U.S. distribution rights for its cryotherapy products via a joint venture entity.
🚩 Red Flags
- High cost of debt: The company is financing acquisitions using a term loan bearing a high interest rate of 13.25% per annum.
- Debt-funded growth: The $5M investment was sourced from a recent $15.5M borrowing rather than organic cash flow.
📋 Key Facts
- Sanara CMP LLC purchased 100,674.72 common units of ChemoMouthpiece, LLC (CMp) for $5.0 million.
- The acquisition represents approximately 6.64% of CMp's issued and outstanding membership interests.
- SI Healthcare Technologies, LLC (a 50/50 JV between Sanara and InfuSystem) is appointed as the sole exclusive U.S. distributor for CMp's products for a five-year term.
- The $5.0 million investment was funded via a recent $15.5 million second borrowing under an existing Term Loan Agreement with CRG Servicing LLC.
- CMp's primary product is the Chemo Mouthpiece®, a 510(k) cleared device for treating oral mucositis.
Sanara MedTech Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024 and to provide an investor presentation.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The company issued a press release regarding financial results (Exhibit 99.1).
- An investor presentation was furnished for use in upcoming meetings and a webcast scheduled for August 13, 2024 (Exhibit 99.2).
Sanara MedTech Inc. is furnishing an investor presentation in connection with a webcast held on June 20, 2024. This filing is intended to satisfy Regulation FD disclosure requirements.
📋 Key Facts
- The company held/is holding a webcast on June 20, 2024, at 11:00 a.m. CT.
- An investor presentation (Exhibit 99.1) was provided to supplement the filing.
- Information furnished under Item 7.01 is not considered 'filed' for purposes of Section 18 liability.
Sanara MedTech Inc. announced that shareholders approved the 2024 Omnibus Long-Term Incentive Plan (LTIP) during the company's Annual Meeting of Shareholders held on June 12, 2024.
📋 Key Facts
- Shareholders approved the 2024 LTIP at the Annual Meeting on June 12, 2024.
- The 2024 LTIP became effective immediately upon approval on June 12, 2024.
- Details of the plan are contained in the company's Definitive Proxy Statement filed on April 15, 2024, and supplemented on May 15, 2024.
Sanara MedTech Inc. reported the results of its 2024 Annual Meeting of Shareholders held on June 12, 2024. The meeting resulted in the successful election of eight directors and the approval of an amended Certificate of Formation and a new Long-Term Incentive Plan.
🚩 Red Flags
- Proposal 3 (filling a board vacancy) was not presented at the meeting because the Board did not effectuate the previously planned board size increase.
📋 Key Facts
- Annual Meeting held on June 12, 2024, with 7,029,596 shares present or represented by proxy.
- Eight directors were elected to one-year terms: Ronald T. Nixon, Robert A. DeSutter, Roszell Mack III, Eric D. Major, Sara N. Ortwein, Ann Beal Salamone, James W. Stuckert, and Eric D. Tanzberger.
- Shareholders approved an amendment/restatement of the Certificate of Formation to allow the number of directors to be fixed by the Bylaws; effective June 13, 2024.
- The 2024 Long-Term Incentive Plan was approved by shareholders.
- Weaver and Tidwell, L.L.P. was ratified as the independent registered public accounting firm for fiscal year 2024.
Sanara MedTech Inc. announced the formalization of a separation agreement with former CEO Zachary B. Fleming following his resignation on May 10, 2024. The agreement includes significant severance benefits including 12 months of base salary and COBRA premiums.
🚩 Red Flags
- CEO departure often signals internal instability or strategic shifts in micro-cap companies.
- Significant cash outflow for severance (12 months of base salary) during a period of leadership transition.
📋 Key Facts
- Zachary B. Fleming resigned as CEO effective May 10, 2024.
- The Company entered into a Separation Agreement and General Release on May 29, 2024.
- Severance includes cash payment equal to 12 months of base salary paid in installments over a 12-month period.
- Company will pay COBRA health insurance premiums for Mr. Fleming and dependents during the severance period.
- 50% of unvested restricted stock shares will continue to vest on the original schedule, with some accelerated vesting used to cover tax withholdings.
Sanara MedTech Inc. announced the immediate resignation of CEO Zachary B. Fleming and the appointment of Executive Chairman Ronald T. Nixon as interim CEO. The company also released its Q1 2024 financial results.
🚩 Red Flags
- Immediate departure of the Chief Executive Officer.
- Complexity in executive compensation/retention: The Board modified vesting schedules for unvested shares to facilitate the exit, which can sometimes signal tension or a rushed transition.
- Leadership instability: Transitioning from a CEO to an interim Chairman-led structure often indicates a period of strategic pivot or internal reorganization.
📋 Key Facts
- CEO Zachary B. Fleming resigned effective May 10, 2024.
- The Board modified vesting provisions for Mr. Fleming's restricted stock awards, allowing 50% of unvested shares to continue vesting subject to a separation agreement.
- Executive Chairman Ronald T. Nixon appointed as interim CEO effective May 12, 2024.
- Company released Q1 2024 financial results and an investor presentation on May 13, 2024.
Sanara MedTech Inc. entered into a new $55.0 million senior secured term loan agreement on April 17, 2024, to refinance existing debt and fund working capital/acquisitions. The deal includes significant interest costs and strict revenue-based financial covenants.
🚩 Red Flags
- High interest rate of 13.25% suggests high perceived risk by lenders.
- Strict revenue-based covenants: The company must hit escalating annual revenue targets (e.g., $60M in 2024, $75M in 2025) to avoid default.
- Significant fees: Total upfront and back-end fees amount to 8.5% of the principal.
- Collateralization: All company assets and intellectual property are pledged as security.
📋 Key Facts
- Entered into a Term Loan Agreement with CRG Servicing LLC as administrative agent.
- Total facility size: $55.0 million (First borrowing of $15.0 million on April 17, 2024; up to $40.0 million in subsequent borrowings through June 30, 2025).
- Interest rate: 13.25% per annum (subject to a 4.0% increase upon default).
- Maturity date: March 30, 2029.
- Upfront fee of 1.50% and a back-end fee of 7.00% of the aggregate principal amount.
- Security: A lien on substantially all assets, including intellectual property.
- Financial Covenants: Minimum liquidity > $3.0 million (or minimum cash required by other debt) and annual revenue targets starting at $60M in 2024, scaling to $105M+ annually thereafter.
Sanara MedTech Inc. announced the appointment of Jacob A. Waldrop as Chief Operating Officer, effective April 15, 2024. The filing details his compensation package, which includes a base salary and various equity and performance-based incentives.
📋 Key Facts
- Jacob A. Waldrop appointed as COO, effective April 15, 2024.
- Annual base salary set at $315,000.
- Eligible for annual restricted stock award up to 75% of base salary and an annual cash bonus up to 75% of base salary.
- One-time restricted stock award valued at $100,000 to be granted within 30 days of the effective date.
- Severance package includes one year of base salary in the event of termination without cause or certain change of control scenarios.
Sanara MedTech Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023. The filing includes a press release and an investor presentation scheduled for a webcast on March 26, 2024.
📋 Key Facts
- Report date: March 25, 2024
- Reporting period covered: Quarter and Year ended December 31, 2023
- Included Exhibit 99.1: Press Release regarding financial results
- Included Exhibit 99.2: Investor Presentation for upcoming webcast on March 26, 2024
Sanara MedTech Inc. has adopted amended and restated bylaws to modernize corporate governance in alignment with the Texas Business Organizations Code. The changes include updated procedures for shareholder meetings, nominations, and director removal.
🚩 Red Flags
- Increased shareholder threshold for calling special meetings (10% to 25%) may be viewed as a defensive measure against activist investors.
📋 Key Facts
- Board of Directors adopted Amended and Restated Bylaws effective March 21, 2024.
- Increased the threshold for shareholders to call a special meeting from 10% to 25% of issued and outstanding shares.
- Implemented new advance notice provisions for shareholder proposals and director nominations.
- Adjusted record date ranges for meetings/dividends from a maximum of 50 to 60 days.
- Changed director removal requirement from a majority of shares present at a meeting to a majority of all shares entitled to vote.
- Authorized the Chairman of the Board to call special meetings.
- Adopted provisions regarding exclusive forum and consent to jurisdiction for derivative claims.
Sanara MedTech Inc. issued a press release announcing preliminary financial results for the fourth quarter and full year of 2023.
📋 Key Facts
- Report date: February 22, 2024
- Subject matter: Preliminary financial results for Q4 and FY 2023
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 liability.